Fixed-term

Details Uncontrolled cell growth is a hallmark of cancer. Efforts have been made to restrict tumour growth by pharmacologically inhibiting a master driver of cell growth, the Target of Rapamycin Complex 1 (TORC1/mTORC1) kinase complex. However, the limited success of this approach was explained by recent evidence showing that inhibiting TORC1 activity towards some substrates actually benefits cancer cells. Specifically, inhibiting TORC1-mediated phosphorylation of the TFEB transcription factor promotes invasion of triple-negative breast cancer cells [PMID: 39729986]. Therefore, effective treatment of invasive/metastatic cancer requires redesign of the therapeutic strategy to inhibit TORC1 activity towards its canonical substrates (such as S6K and 4EBP1, regulators of global protein synthesis), while maintaining its activity towards TFEB. This strategy reflects a recent paradigm shift in the TORC1 research field, pioneered by my group, in understanding that TORC1 can operate in a substrate-selective manner. For both yeast and mammalian cells, evidence has emerged for functionally distinct subcellular TORC1 pools, lysosomal and non-lysosomal [PMID: 30527664][PMID: 39385049]. Each TORC1 pool phosphorylates distinct sets of substrates under control of pool-specific upstream regulators, including G protein-coupled receptors (GPCRs) [doi.org/10.1101/2024.09.18.613687]. This project will elucidate the molecular mechanisms of pool-specific TORC1 regulation utilizing our unique yeast system, in which the activities of the two TORC1 pools can be separately monitored and manipulated. We will then apply the findings to breast cancer cells to examine if pool-specific TORC1 manipulation can suppress cancer growth without promoting invasion. This project potentially revolutionizes our therapeutic approach to cancer by exploiting substrate-selective TORC1 signalling. The student will benefit from the interdisciplinary supervisory team and be trained on skills and knowledge in yeast genetics, image analysis, and cancer cell biology, which are widely valued in academia, food/biotechnology, and pharmaceutical industries. Informal enquiries are encouraged, please contact Dr Riko Hatakeyama (riko.hatakeyama@abdn.ac.uk) for further information. ELIGIBILITY: Applicants should hold a minimum of a 2:1 UK Honours degree (or international equivalent) in a relevant subject. Those with a 2:2 UK Honours degree (or international equivalent) may be considered, provided they have (or are expected to achieve) a Distinction or Commendation at master’s level. We actively encourage applications from diverse career paths and backgrounds and across all sections of the community, regardless of age, disability, ethnicity, gender, gender expression, sexual orientation and transgender status, amongst other protected characteristics. Application Procedure Important note: This project is open only to applicants eligible for the Home/UK fee rate. This includes EU students who hold settled or pre-settled status and meet the relevant residency criteria. To apply, please submit the following documents via email to smmsn-pgrenquiries@abdn.ac.uk A cover letter addressed to the supervisor of the project you’re applying for. An up-to-date CV detailing your academic qualifications, employment history, and any other relevant experience. Please ensure your current permanent address is clearly stated, as this will be used to determine your fee status. Clear copies of your degree certificates and transcripts (if available). Evidence of settled or pre-settled status (if applicable). Please send your application with documents attached as a single email with the subject line: “JAMT Riko Hatakeyama – [Your Name]” The deadline for applications is 23:59 GMT on 14th June 2026. Please note that incomplete applications will not be considered. For any enquiries regarding your application or the application process, please contact smmsn-pgrenquiries@abdn.ac.uk Funding Notes This competitively funded research project is one of six opportunities currently advertised by the University of Aberdeen, seeking exceptional candidates. The James Alexander Mearns Trust (JAMT) will fund the project that attracts the most promising applicant. The fully funded position includes UK/Home tuition fees, research costs, and a tax-free doctoral stipend of £21,805 for the 2026/2027 academic year (increases annually). The project is expected to start in October 2026. References • Atkinson SJ, Negoita F, Ritchie WV, Thompson K, Sakamoto K, Thompson D, Hislop JN, Hatakeyama R. (2024) Substrate-specific regulation of the mTORC1 pathway by G protein-coupled receptors. BioRxiv. doi: https://www.biorxiv.org/content/10.1101/2024.09.18.613687. • Muneshige K and Hatakeyama R. (2025) Vacuoles provide the source membrane for TORC1-containing signaling endosomes. Journal of Cell Biology. 224 (5): e202407021. • Hatakeyama R, Péli-Gulli MP, Hu Z, Jaquenoud M, Garcia Osuna GM, Sardu A, Dengjel J, De Virgilio C. (2019) Spatially distinct pools of TORC1 balance protein homeostasis. Molecular Cell. 73:325-338. Apply Now

Details This PhD will reveal the consequences of ageing-acquired and chemotherapy-induced somatic mutations for T cell function and immune regulatory pathways in health and disease. Background Older age is a major risk factor for cancers, autoimmune disease, and mortality following infections. Consequently, older people require more care, significantly adding to rising healthcare costs worldwide. As we get older our immune system ceases to function as efficiently compared to when we were younger, and for cancer patients’, chemotherapy can significantly impact immune function. Therefore, finding ways to monitor and promote healthy immune ageing will improve quality of life for cancer patients and older people, and reduce pressure on healthcare systems. Key to the pathology of the above diseases are T lymphocytes of the adaptive immune system, either via killing malignant or pathogen-infected cells, secreting paracrine signalling proteins like cytokines, or by dysregulated activation in the case of autoimmunity. Memory T cells are long lived, required for vaccine immunity, and go through multiple rounds of cell division during the clonal expansion of an immune response, and homeostatically to maintain durable immune memory against pathogens. Somatic mutations are individually rare but accumulate at a steady rate in the DNA of T cells as a person ages. Memory T lymphocytes that provide durable immunity, accumulate more mutations than naïve T cells [1]. In tandem, cytotoxic chemotherapy has been shown to induce extensive somatic mutations in haematopoietic cells [2,3], suggesting T cells of cancer patients are significantly compromised, weakening their ability to fight cancer and infections, and form effective immune memory after vaccination. New data from the Morgan lab suggests T cell somatic mutations burden affects T cell regulation pathways, including mitochondrial function, cytokine signalling and proteostasis. However, in both healthy older people and cancer patients, the impact of mutations on T cell function, immune ageing and cancer outcomes, has not been investigated. While T cell function may be compromised in some cancer patients, the composition of T cell phenotypes varies across patients with different haematological malignancies. In multiple myeloma, there is skew towards clonally expanded effector CD8+ killer T cells, which correlate with response to bispecific T cell engager therapy [4], but which express markers of exhaustion, e.g. PD-1, TOX [5]. However, compared to B cell lymphoma, myeloma patients show relatively low levels of functionally exhausted T cells [6]. To understand the relative consequences of chemotherapy and somatic mutations for T cells from patients with different blood cancers we therefore need to know what the composition of T cell functional states is in these patients. Training Offered This interdisciplinary PhD blends experimentation and computation to deliver patient benefit. The project will provide strong interdisciplinary training in cutting-edge immunology, bioinformatics, microscopy and genomics across the Morgan and Sutherland labs, supported by clinician Dr Gavin Preston. Blending experimentation and computation in the Morgan lab, the trainee will identify somatic mutation drivers of T cell immunosenescence using single-cell RNA-sequencing gaining deep computational biology training. Flow cytometry assay optimisation will develop the student’s experimental immunology skillset guided by the supervisors Preston & Sutherland, while live cell imaging coupled to whole genome sequencing will quantify defects in T cell activation kinetics caused by chemotherapy and somatic mutations. Collectively, these experiments will equip the trainee with all the necessary skills required to embark on a scientific career at the cutting-edge of biomedical research. Moreover, as a joint member of the Morgan and Sutherland labs, with co-supervision from clinician Dr Gavin Preston, the student will interact with biologists, clinicians, bioinformaticians and statisticians, thus providing opportunities for them to broaden their interdisciplinary skillset. Informal enquiries are encouraged, please contact Dr Mike Morgan (michael.morgan@abdn.ac.uk) for further information. Candidate Background: The ideal candidate will be curious, highly motivated, with excellent critical analysis, organisational and communication skills and a strong desire to integrate experimentation and computation to solve challenging biomedical problems. Candidates should have a first-class degree or 2:1 (or equivalent) in a subject related to immunology, cell biology, genomics, genetics, biomedical sciences or a quantitative biomedical subject, e.g. bioinformatics. Previous research lab experience is advantageous, particularly in a genomics or immunology setting involving primary cell culture. Experience with data science and programming is desirable given the interdisciplinary nature of the project; however, training will be given for candidates with no prior programming or statistics experience. We actively encourage applications from diverse career paths and backgrounds and across all sections of the community, regardless of age, disability, ethnicity, gender, gender expression, sexual orientation and transgender status, amongst other protected characteristics. Application Procedure Important note: This project is open only to applicants eligible for the Home/UK fee rate. This includes EU students who hold settled or pre-settled status and meet the relevant residency criteria. To apply, please submit the following documents via email to smmsn-pgrenquiries@abdn.ac.uk A cover letter addressed to the supervisor of the project you’re applying for. An up-to-date CV detailing your academic qualifications, employment history, and any other relevant experience. Please ensure your current permanent address is clearly stated, as this will be used to determine your fee status. Clear copies of your degree certificates and transcripts (if available). Evidence of settled or pre-settled status (if applicable). Please send your application with documents attached as a single email with the subject line: “JAMT Mike Morgan – [Your Name]” The deadline for applications is 23:59 GMT on 14th June 2026. Please note that incomplete applications will not be considered. For any enquiries regarding your application or the application process, please contact smmsn-pgrenquiries@abdn.ac.uk Funding Notes This competitively funded research project is one of six opportunities currently advertised by the University of Aberdeen, seeking exceptional candidates. The James Alexander Mearns Trust (JAMT) will fund the project that attracts the most promising applicant. The fully funded position includes UK/Home tuition fees, research costs, and a tax-free doctoral stipend of £21,805 for the 2026/2027 academic year. The project is expected to start in October 2026. References [1] Machado et al. Nature (2022), https://doi.org/10.1038/s41586-022-05072-7 [2] Mitchell et al. Nature Genetics (2025), https://doi.org/10.1038/s41588-025-02234-x [3] Uryu et al. Nature Genetics (2025), https://doi.org/10.1038/s41588-025-02235-w [4] Friedrich et al. Cancer Cell (20223), https://doi.org/10.1016/j.ccell.2023.02.008 [5] Ledergor et al. Blood (2024), https://doi.org/10.1182/bloodadvances.2023012416 [6] Shasha

Details Applications are invited for a fully funded PhD studentship within the Institute of Medical Sciences at the University of Aberdeen, commencing in October 2026. This project offers an exciting opportunity to investigate the cellular and molecular mechanisms underpinning amyotrophic lateral sclerosis (ALS), with a particular focus on neuroinflammatory processes. ALS (also known as motor neuron disease) is a rapidly progressive neurodegenerative disorder leading to paralysis and ultimately death. Despite significant advances in understanding neuronal vulnerability, ALS remains incurable. Increasing evidence highlights the critical role of non-neuronal cells, particularly microglia and astrocytes, in driving ALS disease processes through neuroinflammatory pathways1, 2. This project will focus on understanding the interplay between microglia, the resident immune cells of the central nervous system, and astrocytes in ALS. Our previous work established the first protocol for co-culturing human induced pluripotent stem cell (iPSC)-derived microglia with motor neurons3, demonstrating that microglia from ALS patients induce motor neuron death4. Emerging data from our group further suggest that ALS patient microglia release signalling molecules that activate astrocytes, which in turn will likely cause neurotoxicity5. These findings point to a potentially critical pathogenic axis involving microglia–astrocyte crosstalk. Building on this foundation, the PhD student will use a fully human, stem cell–based model system to dissect the complex interactions between motor neurons, microglia, and astrocytes. By integrating single-cell transcriptomics, high-throughput imaging, and advanced co-culture approaches, the project aims to uncover key mechanisms by which neuroinflammatory signalling drives neuronal degeneration. The outcomes are expected to provide important insights into ALS pathogenesis and identify novel avenues for therapeutic intervention. The successful candidate will receive comprehensive training in cutting-edge techniques, including human iPSC culture and differentiation, single-cell RNA sequencing, high-content imaging, and advanced microscopy. The student will gain additional valuable skills in experimental design, data analysis, and scientific communication, joining a dynamic and collaborative research environment. Informal enquiries are encouraged. For further information please contact Dr Björn Vahsen (bjorn.vahsen@ndcn.ox.ac.uk) Candidate Background Candidates must have or expect to obtain a 1st class honours or an upper 2:1 in their undergraduate degree in in a relevant discipline such as neuroscience, biology, biomedical sciences, or a related field, as well as a significant level of wet-lab research experience in biology or a related field. Candidates should have a strong interest in neurobiology and neurodegenerative disease, with a particular enthusiasm for understanding cellular and molecular mechanisms of disease. Prior laboratory experience in cell culture and molecular biology/neuroscience techniques is essential. Experience with stem cell models, microscopy, or bioinformatics analyses (e.g. RNA sequencing) would be beneficial but is not required, as full training will be provided. Applicants should demonstrate strong analytical and problem-solving skills, attention to detail, and the ability to work both independently and as part of a team. Good communication skills and a proactive approach to learning are essential. Promoting equality, diversity, and inclusion is at the heart of the University of Aberdeen. We welcome applicants from all backgrounds and actively encourage applications from people with diverse career paths, regardless of age, disability, ethnicity, gender, sexual orientation, or other protected characteristics. Application Procedure Important note: This project is open only to applicants eligible for the Home/UK fee rate. This includes EU students who hold settled or pre-settled status and meet the relevant residency criteria. To apply, please submit the following documents via email to smmsn-pgrenquiries@abdn.ac.uk A cover letter addressed to the supervisor of the project you’re applying for. An up-to-date CV detailing your academic qualifications, employment history, and any other relevant experience. Please ensure your current permanent address is clearly stated, as this will be used to determine your fee status. Clear copies of your degree certificates and transcripts (if available). Evidence of settled or pre-settled status (if applicable). Please send your application with documents attached as a single email with the subject line: “Bjorn Vahsen PhD Studentship – [Your Name]” The deadline for applications is 23:59 GMT on 9th June 2026. Please note that incomplete applications will not be considered. For any enquiries regarding your application or the application process, please contact smmsn-pgrenquiries@abdn.ac.uk Funding Notes This PhD studentship is fully funded by the Margaret Carlaw Trust for 3.5 years. The award includes an annual tax-free stipend (set at £21,416 for the 2026/2027 academic year), Home/UK tuition fees, and an allowance for research consumables. The anticipated start date is October 2026. References 1. Giacomelli, E., et al. Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation. Cell Stem Cell 29, 11–35 (2022). 2. Vahsen, B.F., et al. Non-neuronal cells in amyotrophic lateral sclerosis – from pathogenesis to biomarkers. Nat Rev Neurol 17, 333–348 (2021). 3. Vahsen, B.F., et al. Human iPSC co-culture model to investigate the interaction between microglia and motor neurons. Sci Rep 12, 12606 (2022). 4. Vahsen, B.F., et al. C9orf72-ALS human iPSC microglia are pro-inflammatory and toxic to co-cultured motor neurons via MMP9. Nat Commun 14, 5898 (2023). 5. Liddelow, S.A., et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481–487 (2017). Apply Now

Job Description The Research Fellow appointed will investigate the role of macrophage PTP1B in cholesterol metabolism and cross-talk between the myeloid cells and hepatocytes. He/she will work closely with our clinical collaborators at the University of Aberdeen, but also Leeds and Nantes University in France. They would need to be flexible and able to perform some experiments in collaborators’ laboratories in Liverpool, Dundee as well as Copenhagen, and considering the nature of human derived sample processing and cell sorting, required to be flexible with timing. The post would be particularly suited to an individual that is driven by translational projects that aim to address an unmet clinical need and improve patient outcomes. We are seeking a well-motivated, flexible, enthusiastic individual with an interest in cell signalling, immunology and cardiometabolic diseases. You should have (or be about to obtain) a PhD in Immunology/Cell Biology/Molecular Biology or similar. Ideally, the candidate will have experience in working with clinical samples and translational projects with an impact on patient health. Training will be provided for specialist techniques, however, working with blood and patient samples/data is highly desirable as is work with preclinical models of cardiometabolic disease. Previous experience of tissue culture, flow cytometry, biochemistry and molecular biology techniques would also be important. The successful candidate will exhibit excellent record keeping, a strong grasp of data analysis and statistical tests. They will have experience in academic writing and dissemination of their work. Salary will be at the appropriate point on the Grade 6, £38,784 to £41,064 per annum, pro rata. Informal enquiries should be made to Professor Mirela Delibegovic, FRSE; Regius Chair of Physiology (m.delibegovic@abdn.ac.uk). Prior to employment, the successful candidate must be able to demonstrate their right to work in the UK. This role may be eligible for sponsorship under the Skilled Worker route under the UKVI immigration rules but is dependent on factors specific to the candidate and if tradeable points can be used under the rules. Alternatively, the successful candidate for this post may be eligible to apply for a Global Talent Visa on the UKRI Endorsed Funder route. Information on other visa options is available at https://www.gov.uk/check-uk-visa. Please do not hesitate to contact Grant Rae, HR Adviser (e-mail: grant.rae@abdn.ac.uk) for further information. To apply online for this position visit www.abdn.ac.uk/jobs Job Reference Number: IMS324R The closing date for the receipt of applications is 28 May 2026 The School of Medicine, Medical Sciences and Nutrition embraces a diverse working environment and recognises the many benefits this can bring. Applications from individuals from across all of the equality protected characteristics are encouraged. Please Note If you are unable to complete an application online, please contact the Recruitment Team (HRRecruitment@abdn.ac.uk) to make alternative arrangements for submitting your application within plenty of time before the advertised post closes. Apply Now

Details Prostate cancer is the second leading cause of cancer related death in men, and the number of cases is expected to double by 2040. While current treatments that lower male hormones can slow the disease, many aggressive cancers eventually become resistant, making them much harder to treat. There is an urgent need to identify new drug targets and better ways to detect which cancers are likely to become aggressive. Our research focuses on a group of proteins called G protein-coupled receptors, which sit on the surface of cells and respond to signals in the body: G protein-coupled receptors are already the target of over 30% of existing medicines. We have identified a specific orphan G protein-coupled receptor that carries genetic changes linked to prostate cancer risk and mortality (UK biobank). We aim to understand how this G protein-coupled receptor behaves in prostate cancer, how it is controlled and whether it contributes to aggressive/ therapy-resistant resistance disease. We believe this G protein-coupled receptor could serve as both a new marker to identify aggressive prostate cancer and a promising target for future therapies. This PhD project brings together areas of expertise in G protein-coupled receptors, molecular pharmacology, epigenetics and prostate cancer from the University of Aberdeen, which will offer an optimal training environment and provide the student with a set of highly desirable skills. It is expected that completion of the aims will advance our understanding of the cellular function of G protein-coupled receptors. Informal enquiries are encouraged,, please contact Dr Fiona Murray (fmurray@abdn.ac.uk)t for further information. Candidate Background: The applicant should have a strong interest in pharmacology and drug discovery and an undergraduate qualification in a relevant discipline. Applicants should hold a minimum of a 2:1 UK Honours degree (or international equivalent). Those with a 2:2 UK Honours degree (or international equivalent) may be considered, provided they have (or are expected to achieve) a Distinction or Commendation at master’s level. We actively encourage applications from diverse career paths and backgrounds and across all sections of the community, regardless of age, disability, ethnicity, gender, gender expression, sexual orientation and transgender status, amongst other protected characteristics. Application Procedure Important note: This project is open only to applicants eligible for the Home/UK fee rate. This includes EU students who hold settled or pre-settled status and meet the relevant residency criteria. To apply, please submit the following documents via email to smmsn-pgrenquiries@abdn.ac.uk A cover letter addressed to the supervisor of the project you’re applying for. An up-to-date CV detailing your academic qualifications, employment history, and any other relevant experience. Please ensure your current permanent address is clearly stated, as this will be used to determine your fee status. Clear copies of your degree certificates and transcripts (if available). Evidence of settled or pre-settled status (if applicable). Please send your application with documents attached as a single email with the subject line: “JAMT Fiona Murray – [Your Name]” The deadline for applications is 23:59 GMT on 14th June 2026. Please note that incomplete applications will not be considered. For any enquiries regarding your application or the application process, please contact smmsn-pgrenquiries@abdn.ac.uk Funding Notes This competitively funded research project is one of six opportunities currently advertised by the University of Aberdeen, seeking exceptional candidates. The James Alexander Mearns Trust (JAMT) will fund the project that attracts the most promising applicant. The fully funded position includes UK/Home tuition fees, research costs, and a tax-free doctoral stipend of £21,805 for the 2026/2027 academic year (increases annually). The project is expected to start in October 2026. References 1. Crowley et al., (2021). 2. James et al., (2024). 3. Estébanez-Perpiñá et al., (2021). 4. Murray and Insel. (2013). 5. Claudia et al., (2021). 6. Leeson-Payne et al. (2024). 7. Yin Li et al., (2019). Apply Now

Details Prostate cancer is driven by signalling through the androgen receptor (AR), and advanced disease is treated by suppressing testosterone production and action. Although initially effective, this approach almost always fails as tumours adapt and become therapy‑resistant. Paradoxically, recent clinical trials show that supraphysiological testosterone, delivered as Bipolar Androgen Therapy (BAT), can suppress tumour growth and re‑sensitise cancers to standard hormone therapies in a subset of patients. The biological basis of this response remains poorly understood. This project will investigate how different testosterone concentrations reprogramme AR signalling, and how these changes relate to clinical response to BAT. Building on preliminary RNA‑seq data, the project will test the hypothesis that AR signalling is non‑linear and context‑dependent. Objectives: Define transcriptional programmes activated at low, physiological, and supraphysiological androgen levels using RNA‑seq and systems analysis of biological pathways and gene networks. Identify molecular signatures (AR output, DNA damage response, cell‑cycle stress) associated with supraphysiological androgen exposure. Map these molecular data onto emerging BAT response biomarkers from clinical trials, including baseline testosterone, AR activity, and therapy re‑sensitisation. Our overall aim will be to develop integrative models linking androgen dose, AR transcriptional state, and therapeutic outcome. The project will combine RNA‑seq analysis, bioinformatics, pathway modelling, and translational interpretation, with opportunities to integrate mathematical approaches to understand AR signalling in this context. This work aims to provide a mechanistic framework for patient stratification and biomarker development in testosterone‑based therapies. By linking molecular biology to clinical outcomes, the project addresses an important unmet need in prostate cancer treatment and offers strong training at the interface of cancer biology, data science, and translational research. Informal enquiries are encouraged, please contact Professor Iain McEwan (iain.mcewan@abdn.ac.uk) for further information. Candidate Background: The successful candidate should have a first/2i class honour degree in a relevant biomedical discipline, for example biochemistry, molecular biology, pharmacology or biomedical sciences. A masters in a relevant discipline, including bioinformatics, would be an advantage. We actively encourage applications from diverse career paths and backgrounds and across all sections of the community, regardless of age, disability, ethnicity, gender, gender expression, sexual orientation and transgender status, amongst other protected characteristics. Application Procedure Important note: This project is open only to applicants eligible for the Home/UK fee rate. This includes EU students who hold settled or pre-settled status and meet the relevant residency criteria. To apply, please submit the following documents via email to smmsn-pgrenquiries@abdn.ac.uk A cover letter addressed to the supervisor of the project you’re applying for. An up-to-date CV detailing your academic qualifications, employment history, and any other relevant experience. Please ensure your current permanent address is clearly stated, as this will be used to determine your fee status. Clear copies of your degree certificates and transcripts (if available). Evidence of settled or pre-settled status (if applicable). Please send your application with documents attached as a single email with the subject line: “JAMT Iain McEwan – [Your Name]” The deadline for applications is 23:59 GMT on 14th June 2026. Please note that incomplete applications will not be considered. For any enquiries regarding your application or the application process, please contact smmsn-pgrenquiries@abdn.ac.uk Funding Notes This competitively funded research project is one of six opportunities currently advertised by the University of Aberdeen, seeking exceptional candidates. The James Alexander Mearns Trust (JAMT) will fund the project that attracts the most promising applicant. The fully funded position includes UK/Home tuition fees, research costs, and a tax-free doctoral stipend of £21,805 for the 2026/2027 academic year (increases annually). The project is expected to start in October 2026. References • Gillen AD, Hunter I, Ullner E, McEwan IJ. Mechanistic insights into steroid hormone-mediated regulation of the androgen receptor gene. PLoS One. 2024; 19(8):e0304183. doi: 10.1371/journal.pone.0304183. • Hunter I, Hay CW, Esswein B, Watt K, McEwan IJ. Tissue control of androgen action: The ups and downs of androgen receptor expression. Mol Cell Endocrinol. 2018; 465:27-35. doi: 10.1016/j.mce.2017.08.002. • Safi R et al. Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells. Nat Commun. 2024 Sep 3;15(1):7675. doi: 10.1038/s41467-024-52032-y. Apply Now

Details PhD opportunity: 3D imaging, human lung cancer and the immune-matrix environment This project will combine advanced 3D microscopy, human lung cancer tissue and quantitative image analysis to reveal how the tumour extracellular matrix shapes immune cell exclusion. Background: Immunotherapy has revolutionised lung cancer treatment, but many patients still fail to respond. One of the biggest unanswered questions is why immune cells can enter some tumours but are physically excluded from others. This PhD will investigate how the extracellular matrix (ECM) and immune cells are organised within non-small cell lung cancer (NSCLC), and how this organisation promotes either immune infiltration or immune cell exclusion. In particular, the project will focus on tumour-associated macrophages and the clinically relevant chitinase-like protein YKL-40, a molecule linked to poor prognosis in lung cancer and matrix remodelling in tissues. Using patient-derived archived lung cancer biopsies, decellularised lung ECM scaffolds and state-of-the art microscopy, the student will generate 2D and 3D datasets that reveal how immune cells interact with the tumour matrix in health and disease. What will the project involve: You will work directly with archived and fresh patient-derived lung tumour samples through close collaboration with the Grampian Biorepository and clinicians. Fluorescence and confocal imaging, alongside lightsheet microscopy, and high-content imaging and live-cell tracking will build 2D and 3D maps of immune-ECM organisation in tumours in relation to YKL-40 expression. The project will also involve generation and characterisation of decellularized human lung ECM scaffolds, human immune cell isolation and culture and investigation into how YKL-40 influences macrophages, matrix organisation and immune cell exclusion. A major strength of this project is training in image analysis and digital pathology, including quantitative analysis and deep-learning based segmentation, spatial analysis. This project will work at the intersection of cancer biology, immunology and extracellular matrix biology, providing opportunities to develop cross-cutting skills. Training and environment You will be embedded within the Sutherland and Wilson laboratories, a friendly, ambitious, supportive and collaborative environment with a positive research culture. Alongside specialist hands-on personalised research training and skills development, you will also develop professional and transferable skills that are required for any successful scientific career. You will be supported to attend conferences, present your work, develop independent ideas and publish high-quality research. We strongly encourage potential candidates to get in touch and discuss the project, the lab environment, and wider Aberdeen research community. Please contact Dr Tara Sutherland (tara.sutherland@abdn.ac.uk) for further information. Candidate Background: The ideal student should be enthusiastic, highly motivated with strong problem-solving skills and be happy to work in a collaborative team environment. We are looking for a student with organisational and communication skills and who someone who is curious about science challenges. Ideally candidates whould have experience in immunology, cell biology or matrix biology with a 1st or 2:1 from a bachelor’s degree in biomedical/biological sciences (or equivalent), immunology, cell biology, pharmacology or related field. Experience in the following areas would be an advantage: cell culture, imaging, microscopy, lung pathology, computational analysis. However, a full complement of training will be provided. We actively encourage applications from diverse career paths and backgrounds and across all sections of the community, regardless of age, disability, ethnicity, gender, gender expression, sexual orientation and transgender status, amongst other protected characteristics. Application Procedure Important note: This project is open only to applicants eligible for the Home/UK fee rate. This includes EU students who hold settled or pre-settled status and meet the relevant residency criteria. To apply, please submit the following documents via email to smmsn-pgrenquiries@abdn.ac.uk A cover letter addressed to the supervisor of the project you’re applying for. An up-to-date CV detailing your academic qualifications, employment history, and any other relevant experience. Please ensure your current permanent address is clearly stated, as this will be used to determine your fee status. Clear copies of your degree certificates and transcripts (if available). Evidence of settled or pre-settled status (if applicable). Please send your application with documents attached as a single email with the subject line: “JAMT Tara Sutherland – [Your Name]” The deadline for applications is 23:59 GMT on 14th June 2026. Please note that incomplete applications will not be considered. For any enquiries regarding your application or the application process, please contact smmsn-pgrenquiries@abdn.ac.uk Funding Notes This competitively funded research project is one of six opportunities currently advertised by the University of Aberdeen, seeking exceptional candidates. The James Alexander Mearns Trust (JAMT) will fund the project that attracts the most promising applicant. The fully funded position includes UK/Home tuition fees, research costs, and a tax-free doctoral stipend of £21,805 for the 2026/2027 academic year (increases annually). The project is expected to start in October 2026. References 1. Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer. J. Clin. 74, 229–263. 2. Schoenfeld, A. J. & Hellmann, M. D. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer. Cell. 37, 443–455. 3. Dai, Y. et al. Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer. Cancer. Drug Resist 7, 52. 4. Sautes-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer. 19, 307–325. 5. Berthe, J. et al. Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring. Front. Immunol. 15, 1422206. 6. Wang, J., Sheng, Z., Yang, W. & Cai, Y. Elevated Serum Concentration of Chitinase 3-Like 1 is an Independent Prognostic Biomarker for Poor Survival in Lung Cancer Patients. Cell. Physiol. Biochem. 38, 461–468 (2016). 7. Yu, J. E. et al. Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer. Exp. Mol. Med. 56, 1–18. Apply Now

Details Women’s health has been recognised as a massively underfunded and under researched area and female specific cancers are no exception. Thanks to national campaigns and vaccination strategies there is high awareness and engagement surrounding breast and cervical cancer. However, the awareness of other gynaecological cancers such as endometrial cancer remains relatively low despite being the 4th most common in women in the UK. Importantly, incidences of womb cancer are steadily rising, attributed to several factors including obesity and physical inactivity. Therefore, more research is needed to uncover alternative targets for therapeutic intervention to improve survival and decrease the burden on the NHS. This project presents an exciting and unique PhD opportunity to investigate an understudied G-protein-coupled receptor (GPCR) that plays a critical role in gynaecological health and is elevated in endometrial cancers and correlates with poor prognosis. We have found this GPCR displays unique properties that makes it behave differently from other family members. Understanding how this receptor ‘works’ and what happens when we prevent it from functioning ‘normally’ will inform on how to design better drugs with reduced side effects. The student will receive state of the art training in in vitro techniques including cell culture using immortalised cell lines and transitioning to the isolation of primary cells (from endometrial tumours). Additional techniques will be the development of molecular tools and fluorescent and bioluminescent readouts of receptor function utilising both plate readers and microscopy-based analysis of signalling (e.g. cAMP, calcium, MAP Kinase). These will be complemented by more traditional biochemical approaches to signal transduction (Western blotting, ELISA) in response to chemical inhibition or RNAi and changes in genetics after chronic stimulation (qPCR). The student will also be trained functional readouts such as proliferation, cell migration, etc. Finally, there will be the opportunity to be trained in tissue processing of human samples for genetic analysis (qPCR). Informal enquiries are encouraged, please contact Dr Dawn Tompson (dthompson@abdn.ac.uk) for further information. ELIGIBILITY: Applicants to this project should hold a minimum of a 2:1 UK Honours degree in Pharmacology or a related Biomedical Sciences degree (Physiology, biochemistry, neuroscience etc). Those with a 2:2 UK Honours degree (or international equivalent) may be considered, provided they have (or are expected to achieve) a Distinction or Commendation at master’s level. We actively encourage applications from diverse career paths and backgrounds and across all sections of the community, regardless of age, disability, ethnicity, gender, gender expression, sexual orientation and transgender status, amongst other protected characteristics. Application Procedure Important note: This project is open only to applicants eligible for the Home/UK fee rate. This includes EU students who hold settled or pre-settled status and meet the relevant residency criteria. To apply, please submit the following documents via email to smmsn-pgrenquiries@abdn.ac.uk A cover letter addressed to the supervisor of the project you’re applying for. An up-to-date CV detailing your academic qualifications, employment history, and any other relevant experience. Please ensure your current permanent address is clearly stated, as this will be used to determine your fee status. Clear copies of your degree certificates and transcripts (if available). Evidence of settled or pre-settled status (if applicable). Please send your application with documents attached as a single email with the subject line: “JAMT Dawn Thompson – [Your Name]” The deadline for applications is 23:59 GMT on 14th June 2026. Please note that incomplete applications will not be considered. For any enquiries regarding your application or the application process, please contact smmsn-pgrenquiries@abdn.ac.uk Funding Notes This competitively funded research project is one of six opportunities currently advertised by the University of Aberdeen, seeking exceptional candidates. The James Alexander Mearns Trust (JAMT) will fund the project that attracts the most promising applicant. The fully funded position includes UK/Home tuition fees, research costs, and a tax-free doctoral stipend of £21,805 for the 2026/2027 academic year (increases annually). The project is expected to start in October 2026. Apply Now